{
    "info": {
        "nct_id": "NCT03892044",
        "official_title": "A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular Lymphoma",
        "inclusion_criteria": "* Diagnosis of CLL or small lymphocytic lymphoma (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria AND biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), clinically consistent with Richter?s syndrome (RS) OR histologically diagnosed relapsed or refractory DLBCL including transformed follicular lymphoma (tFL) ineligible for or refractory to platinum containing salvage therapy for the dose escalation portion of the study. For the dose expansion phase only patients with CLL with transformation to DLBCL or tFL will be eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Absolute neutrophil count (ANC) >= 500/uL\n* Platelet count >= 30,000/uL (unless due to bone marrow involvement)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN\n* Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)\n* Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)\n* Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug\n* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study\n* Patients must sign an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Documented infection with human immunodeficiency virus (HIV) or chronic, active hepatitis B or C infection\n* Any chemotherapy or monoclonal antibodies within 14 days or kinase inhibitors (except BTKi) within 5 half-lives before cycle 1, day 1 (C1D1). BTK inhibitors may be continued until 2 days prior to C1D1. Steroids are allowed for palliation of symptoms due to lymphoma\n* Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)\n* Other active malignancies except those treated with curative intent with no active disease at the time of study entry or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)\n* New York Heart Association (NYHA) class III/IV heart disease or other significant medical condition or organ system dysfunction which could compromise the subject?s safety or put the study outcomes at undue risk\n* Uncontrolled systemic infection\n* Unable to swallow capsules or significant malabsorption syndrome, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction at the time of screening\n* Patients who are pregnant or breastfeeding\n* Patients with known central nervous system (CNS) involvement by CLL or lymphoma\n* Patients who have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to C1D1 or have active graft-versus-host disease are excluded",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count >= 30,000/uL (unless due to bone marrow involvement)",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count >= 30,000/uL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30000,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count >= 30,000/uL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30000,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) >= 500/uL",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) >= 500/uL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) >= 500/uL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) =< 2.5 ULN",
                        "criterion": "aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) =< 2.5 ULN",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) =< 2.5 ULN",
                        "criterion": "aspartate aminotransferase (AST)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) =< 2.5 ULN",
                        "criterion": "alanine aminotransferase (ALT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must sign an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study",
                "criterions": [
                    {
                        "exact_snippets": "sign an informed consent document",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "indicating that they understand the purpose of and procedures required for the study, including biomarkers",
                        "criterion": "understanding of study purpose and procedures",
                        "requirement": {
                            "requirement_type": "understanding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing to participate in the study",
                        "criterion": "willingness to participate",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "sign an informed consent document",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "indicating that they understand the purpose of and procedures required for the study, including biomarkers",
                        "criterion": "understanding of study purpose and procedures",
                        "requirement": {
                            "requirement_type": "understanding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing to participate in the study",
                        "criterion": "willingness to participate",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential ... must be practicing a highly effective method of birth control during and after the study ... For females, these restrictions apply for 1 month after the last dose of study drug.",
                        "criterion": "women of childbearing potential",
                        "requirement": {
                            "requirement_type": "birth control method",
                            "expected_value": "highly effective method"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential ... must be practicing a highly effective method of birth control during and after the study ... For females, these restrictions apply for 1 month after the last dose of study drug.",
                        "criterion": "women of childbearing potential",
                        "requirement": {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month after last dose"
                            }
                        }
                    },
                    {
                        "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                        "criterion": "sexually active men",
                        "requirement": {
                            "requirement_type": "birth control method",
                            "expected_value": "highly effective method"
                        }
                    },
                    {
                        "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                        "criterion": "sexually active men",
                        "requirement": {
                            "requirement_type": "sperm donation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                        "criterion": "sexually active men",
                        "requirement": {
                            "requirement_type": "duration of restrictions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months after last dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Women of childbearing potential ... must be practicing a highly effective method of birth control during and after the study ... For females, these restrictions apply for 1 month after the last dose of study drug.",
                                "criterion": "women of childbearing potential",
                                "requirement": {
                                    "requirement_type": "birth control method",
                                    "expected_value": "highly effective method"
                                }
                            },
                            {
                                "exact_snippets": "Women of childbearing potential ... must be practicing a highly effective method of birth control during and after the study ... For females, these restrictions apply for 1 month after the last dose of study drug.",
                                "criterion": "women of childbearing potential",
                                "requirement": {
                                    "requirement_type": "duration of birth control use",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "month after last dose"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                                "criterion": "sexually active men",
                                "requirement": {
                                    "requirement_type": "birth control method",
                                    "expected_value": "highly effective method"
                                }
                            },
                            {
                                "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                                "criterion": "sexually active men",
                                "requirement": {
                                    "requirement_type": "sperm donation",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "men who are sexually active must be practicing a highly effective method of birth control during and after the study ... Men must agree to not donate sperm during and after the study. ... For males, these restrictions apply for 3 months after the last dose of study drug",
                                "criterion": "sexually active men",
                                "requirement": {
                                    "requirement_type": "duration of restrictions",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Patients who are pregnant or breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "Patients who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with known central nervous system (CNS) involvement by CLL or lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement by CLL or lymphoma",
                        "criterion": "central nervous system (CNS) involvement by CLL or lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "known central nervous system (CNS) involvement by CLL or lymphoma",
                        "criterion": "central nervous system (CNS) involvement by CLL or lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled systemic infection",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled systemic infection",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled systemic infection",
                        "criterion": "systemic infection",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Documented infection with human immunodeficiency virus (HIV) or chronic, active hepatitis B or C infection",
                "criterions": [
                    {
                        "exact_snippets": "Documented infection with human immunodeficiency virus (HIV)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented infection with human immunodeficiency virus (HIV)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic, active hepatitis B or C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Documented infection with human immunodeficiency virus (HIV)",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Documented infection with human immunodeficiency virus (HIV)",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "documentation",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "chronic, active hepatitis B or C infection",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Unable to swallow capsules or significant malabsorption syndrome, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction at the time of screening",
                "criterions": [
                    {
                        "exact_snippets": "Unable to swallow capsules",
                        "criterion": "ability to swallow capsules",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "significant malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "significant malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "symptomatic inflammatory bowel disease",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "partial or complete bowel obstruction at the time of screening",
                        "criterion": "bowel obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Unable to swallow capsules",
                            "criterion": "ability to swallow capsules",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "significant malabsorption syndrome",
                                "criterion": "malabsorption syndrome",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "significant"
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "significant malabsorption syndrome",
                                    "criterion": "malabsorption syndrome",
                                    "requirement": {
                                        "requirement_type": "presence",
                                        "expected_value": false
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "symptomatic inflammatory bowel disease",
                            "criterion": "inflammatory bowel disease",
                            "requirement": {
                                "requirement_type": "symptomatic",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "ulcerative colitis",
                            "criterion": "ulcerative colitis",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "partial or complete bowel obstruction at the time of screening",
                            "criterion": "bowel obstruction",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* New York Heart Association (NYHA) class III/IV heart disease or other significant medical condition or organ system dysfunction which could compromise the subject?s safety or put the study outcomes at undue risk",
                "criterions": [
                    {
                        "exact_snippets": "New York Heart Association (NYHA) class III/IV heart disease",
                        "criterion": "NYHA heart disease class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    },
                    {
                        "exact_snippets": "other significant medical condition or organ system dysfunction which could compromise the subject?s safety or put the study outcomes at undue risk",
                        "criterion": "significant medical condition or organ system dysfunction",
                        "requirement": {
                            "requirement_type": "potential to compromise safety or study outcomes",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "New York Heart Association (NYHA) class III/IV heart disease",
                                "criterion": "NYHA heart disease class",
                                "requirement": {
                                    "requirement_type": "class",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "other significant medical condition or organ system dysfunction which could compromise the subject?s safety or put the study outcomes at undue risk",
                                "criterion": "significant medical condition or organ system dysfunction",
                                "requirement": {
                                    "requirement_type": "potential to compromise safety or study outcomes",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)",
                "criterions": [
                    {
                        "exact_snippets": "Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)",
                        "criterion": "toxicity from previous therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "grade"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)",
                        "criterion": "toxicity from previous therapy",
                        "requirement": {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)",
                                    "criterion": "toxicity from previous therapy",
                                    "requirement": {
                                        "requirement_type": "severity",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": 1,
                                                    "unit": "grade"
                                                }
                                            ]
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline)",
                                    "criterion": "toxicity from previous therapy",
                                    "requirement": {
                                        "requirement_type": "resolution",
                                        "expected_value": true
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "or_criteria": [
                        {
                            "exact_snippets": "Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                            "criterion": "liver involvement",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                            "criterion": "hemolysis",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                            "criterion": "Gilbert?s disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease)",
                            "criterion": "total bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "ULN"
                                }
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosis of CLL or small lymphocytic lymphoma (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria AND biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), clinically consistent with Richter?s syndrome (RS) OR histologically diagnosed relapsed or refractory DLBCL including transformed follicular lymphoma (tFL) ineligible for or refractory to platinum containing salvage therapy for the dose escalation portion of the study. For the dose expansion phase only patients with CLL with transformation to DLBCL or tFL will be eligible",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of CLL or small lymphocytic lymphoma (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria",
                        "criterion": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "CLL",
                                "SLL"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of CLL or small lymphocytic lymphoma (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria",
                        "criterion": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "IWCLL 2008"
                        }
                    },
                    {
                        "exact_snippets": "biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), clinically consistent with Richter?s syndrome (RS)",
                        "criterion": "transformation to diffuse large B cell lymphoma (DLBCL)",
                        "requirement": {
                            "requirement_type": "confirmation_method",
                            "expected_value": "biopsy proven"
                        }
                    },
                    {
                        "exact_snippets": "biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), clinically consistent with Richter?s syndrome (RS)",
                        "criterion": "transformation to diffuse large B cell lymphoma (DLBCL)",
                        "requirement": {
                            "requirement_type": "clinical_consistency",
                            "expected_value": "Richter's syndrome"
                        }
                    },
                    {
                        "exact_snippets": "histologically diagnosed relapsed or refractory DLBCL including transformed follicular lymphoma (tFL)",
                        "criterion": "relapsed or refractory DLBCL or transformed follicular lymphoma (tFL) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "relapsed DLBCL",
                                "refractory DLBCL",
                                "transformed follicular lymphoma"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "histologically diagnosed relapsed or refractory DLBCL including transformed follicular lymphoma (tFL)",
                        "criterion": "relapsed or refractory DLBCL or transformed follicular lymphoma (tFL) diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_method",
                            "expected_value": "histologically diagnosed"
                        }
                    },
                    {
                        "exact_snippets": "ineligible for or refractory to platinum containing salvage therapy",
                        "criterion": "eligibility or response to platinum containing salvage therapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "ineligible for or refractory to platinum containing salvage therapy",
                        "criterion": "eligibility or response to platinum containing salvage therapy",
                        "requirement": {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For the dose expansion phase only patients with CLL with transformation to DLBCL or tFL will be eligible",
                        "criterion": "eligibility for dose expansion phase",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "CLL with transformation to DLBCL",
                                "CLL with transformation to tFL"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "serum (beta-human chorionic gonadotropin [beta-hCG])",
                                "urine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    },
                    {
                        "exact_snippets": "Women who are pregnant ... are ineligible for this study",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... breastfeeding are ineligible for this study",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Other active malignancies except those treated with curative intent with no active disease at the time of study entry or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)",
                "criterions": [
                    {
                        "exact_snippets": "Other active malignancies except those treated with curative intent with no active disease at the time of study entry",
                        "criterion": "other active malignancies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "except those treated with curative intent with no active disease at the time of study entry",
                        "criterion": "other malignancies treated with curative intent",
                        "requirement": {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "except those treated with curative intent with no active disease at the time of study entry",
                        "criterion": "other malignancies treated with curative intent",
                        "requirement": {
                            "requirement_type": "disease_status_at_study_entry",
                            "expected_value": "no active disease"
                        }
                    },
                    {
                        "exact_snippets": "or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)",
                        "criterion": "other malignancies at low risk of progression or recurrence",
                        "requirement": {
                            "requirement_type": "risk_of_progression_or_recurrence",
                            "expected_value": "low"
                        }
                    },
                    {
                        "exact_snippets": "or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)",
                        "criterion": "other malignancies at low risk of progression or recurrence",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "over the next 2 years"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "other active malignancies except those treated with curative intent with no active disease at the time of study entry",
                                "criterion": "other active malignancies",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "except those treated with curative intent with no active disease at the time of study entry",
                                            "criterion": "other malignancies treated with curative intent",
                                            "requirement": {
                                                "requirement_type": "treatment_intent",
                                                "expected_value": "curative"
                                            }
                                        },
                                        {
                                            "exact_snippets": "except those treated with curative intent with no active disease at the time of study entry",
                                            "criterion": "other malignancies treated with curative intent",
                                            "requirement": {
                                                "requirement_type": "disease_status_at_study_entry",
                                                "expected_value": "no active disease"
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)",
                                    "criterion": "other malignancies at low risk of progression or recurrence",
                                    "requirement": {
                                        "requirement_type": "risk_of_progression_or_recurrence",
                                        "expected_value": "low"
                                    }
                                },
                                {
                                    "exact_snippets": "or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance)",
                                    "criterion": "other malignancies at low risk of progression or recurrence",
                                    "requirement": {
                                        "requirement_type": "timeframe",
                                        "expected_value": "over the next 2 years"
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients who have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to C1D1 or have active graft-versus-host disease are excluded",
                "criterions": [
                    {
                        "exact_snippets": "have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to C1D1",
                        "criterion": "autologous or allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have active graft-versus-host disease",
                        "criterion": "graft-versus-host disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to C1D1",
                        "criterion": "autologous or allogeneic stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have active graft-versus-host disease",
                        "criterion": "graft-versus-host disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any chemotherapy or monoclonal antibodies within 14 days or kinase inhibitors (except BTKi) within 5 half-lives before cycle 1, day 1 (C1D1). BTK inhibitors may be continued until 2 days prior to C1D1. Steroids are allowed for palliation of symptoms due to lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "Any chemotherapy ... within 14 days ... before cycle 1, day 1 (C1D1)",
                        "criterion": "chemotherapy administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "monoclonal antibodies within 14 days ... before cycle 1, day 1 (C1D1)",
                        "criterion": "monoclonal antibody administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "kinase inhibitors (except BTKi) within 5 half-lives before cycle 1, day 1 (C1D1)",
                        "criterion": "kinase inhibitor (except BTKi) administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    },
                    {
                        "exact_snippets": "BTK inhibitors may be continued until 2 days prior to C1D1",
                        "criterion": "BTK inhibitor administration",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Steroids are allowed for palliation of symptoms due to lymphoma",
                        "criterion": "steroid use for palliation of lymphoma symptoms",
                        "requirement": {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Any chemotherapy ... within 14 days ... before cycle 1, day 1 (C1D1)",
                            "criterion": "chemotherapy administration",
                            "requirement": {
                                "requirement_type": "time since last administration",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 14,
                                    "unit": "days"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "monoclonal antibodies within 14 days ... before cycle 1, day 1 (C1D1)",
                            "criterion": "monoclonal antibody administration",
                            "requirement": {
                                "requirement_type": "time since last administration",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 14,
                                    "unit": "days"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "kinase inhibitors (except BTKi) within 5 half-lives before cycle 1, day 1 (C1D1)",
                            "criterion": "kinase inhibitor (except BTKi) administration",
                            "requirement": {
                                "requirement_type": "time since last administration",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 5,
                                    "unit": "half-lives"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "BTK inhibitors may be continued until 2 days prior to C1D1",
                            "criterion": "BTK inhibitor administration",
                            "requirement": {
                                "requirement_type": "time since last administration",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "days"
                                }
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}